Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II rivaroxaban for livedoid vasculopathy (pain on VAS)
2012-000108-13Phase 2Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rivaroxaban in livedoid vasculopathy (LV), sponsored by Universitätsklinikum Münster. Primary endpoint: Change in local pain on VAS at 12 weeks. Started Nov 2012; status: completed.
02
Drugs
rivaroxaban
03
Conditions
livedoid vasculopathy (LV)
Beyond the preview
Go deeper on 2012-000108-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000108-13.